Pieterjan Debie1, Marian Vanhoeij2, Natalie Poortmans2, Janik Puttemans3, Kris Gillis3,4, Nick Devoogdt3, Tony Lahoutte3,5, Sophie Hernot3. 1. Laboratory for In vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laabeeklaan 103, 1090, Jette, Brussels, Belgium. pieterjan.debie91@gmail.com. 2. Department of Oncological Surgery, UZ Brussel, Brussels, Belgium. 3. Laboratory for In vivo Cellular and Molecular Imaging, ICMI-BEFY, Vrije Universiteit Brussel, Laabeeklaan 103, 1090, Jette, Brussels, Belgium. 4. Department of Cardiology, UZ Brussel, Brussels, Belgium. 5. Department of Nuclear Medicine, UZBrussel, Brussels, Belgium.
Abstract
PURPOSE: Debulking followed by combination chemotherapy is currently regarded as the most effective treatment for advanced ovarian cancer. Prognosis depends drastically on the degree of debulking. Accordingly, near-infrared (NIR) fluorescence imaging has been proposed to revolutionize cancer surgery by acting as a sensitive, specific, and real-time tool enabling visualization of cancer lesions. We have previously developed a NIR-labeled nanobody that allows fast, specific, and high-contrast imaging of HER2-positive tumors. In this study, we applied this tracer during fluorescence-guided surgery in a mouse model and investigated the effect on surgical efficiency. PROCEDURES: 0.5 × 106 SKOV3.IP1-Luc+ cells were inoculated intraperitoneally in athymic mice and were allowed to grow for 30 days. Two nanomoles of IRDye800CW-anti-HER2 nanobody was injected intravenously. After 1h30, mice were killed, randomized in two groups, and subjected to surgery. In the first animal group (n = 7), lesions were removed by a conventional surgical protocol, followed by excision of remaining fluorescent tissue using a NIR camera. The second group of mice (n = 6) underwent directly fluorescence-guided surgery. Bioluminescence imaging was performed before and after surgery. Resected tissue was categorized as visualized during conventional surgery or not, fluorescent or not, and bioluminescent positive or negative. RESULTS: Fluorescence imaging allowed clear visualization of tumor nodules within the abdomen, up to submillimeter-sized lesions. Fluorescence guidance resulted in significantly reduced residual tumor as compared to conventional surgery. Moreover, sensitivity increased from 59.3 to 99.0 %, and the percentage of false positive lesions detected decreased from 19.6 to 7.1 %. CONCLUSIONS: This study demonstrates the advantage of intraoperative fluorescence imaging using nanobody-based tracers on the efficiency of debulking surgery.
PURPOSE: Debulking followed by combination chemotherapy is currently regarded as the most effective treatment for advanced ovarian cancer. Prognosis depends drastically on the degree of debulking. Accordingly, near-infrared (NIR) fluorescence imaging has been proposed to revolutionize cancer surgery by acting as a sensitive, specific, and real-time tool enabling visualization of cancer lesions. We have previously developed a NIR-labeled nanobody that allows fast, specific, and high-contrast imaging of HER2-positive tumors. In this study, we applied this tracer during fluorescence-guided surgery in a mouse model and investigated the effect on surgical efficiency. PROCEDURES: 0.5 × 106 SKOV3.IP1-Luc+ cells were inoculated intraperitoneally in athymic mice and were allowed to grow for 30 days. Two nanomoles of IRDye800CW-anti-HER2 nanobody was injected intravenously. After 1h30, mice were killed, randomized in two groups, and subjected to surgery. In the first animal group (n = 7), lesions were removed by a conventional surgical protocol, followed by excision of remaining fluorescent tissue using a NIR camera. The second group of mice (n = 6) underwent directly fluorescence-guided surgery. Bioluminescence imaging was performed before and after surgery. Resected tissue was categorized as visualized during conventional surgery or not, fluorescent or not, and bioluminescent positive or negative. RESULTS: Fluorescence imaging allowed clear visualization of tumor nodules within the abdomen, up to submillimeter-sized lesions. Fluorescence guidance resulted in significantly reduced residual tumor as compared to conventional surgery. Moreover, sensitivity increased from 59.3 to 99.0 %, and the percentage of false positive lesions detected decreased from 19.6 to 7.1 %. CONCLUSIONS: This study demonstrates the advantage of intraoperative fluorescence imaging using nanobody-based tracers on the efficiency of debulking surgery.
Authors: Anne C van Leeuwen; Tessa Buckle; Gavin Bendle; Lenka Vermeeren; Renato Valdés Olmos; Henk G van de Poel; Fijs W B van Leeuwen Journal: J Biomed Opt Date: 2011 Jan-Feb Impact factor: 3.170
Authors: Anneleen Blykers; Steve Schoonooghe; Catarina Xavier; Kevin D'hoe; Damya Laoui; Matthias D'Huyvetter; Ilse Vaneycken; Frederik Cleeren; Guy Bormans; Johannes Heemskerk; Geert Raes; Patrick De Baetselier; Tony Lahoutte; Nick Devoogdt; Jo A Van Ginderachter; Vicky Caveliers Journal: J Nucl Med Date: 2015-06-11 Impact factor: 10.057
Authors: Laetitia E Lamberts; Maximillian Koch; Johannes S de Jong; Arthur L L Adams; Jürgen Glatz; Mariëtte E G Kranendonk; Anton G T Terwisscha van Scheltinga; Liesbeth Jansen; Jakob de Vries; Marjolijn N Lub-de Hooge; Carolien P Schröder; Annelies Jorritsma-Smit; Matthijs D Linssen; Esther de Boer; Bert van der Vegt; Wouter B Nagengast; Sjoerd G Elias; Sabrina Oliveira; Arjen J Witkamp; Willem P Th M Mali; Elsken Van der Wall; Paul J van Diest; Elisabeth G E de Vries; Vasilis Ntziachristos; Gooitzen M van Dam Journal: Clin Cancer Res Date: 2016-11-09 Impact factor: 12.531
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Israt S Alam; Idan Steinberg; Ophir Vermesh; Nynke S van den Berg; Eben L Rosenthal; Gooitzen M van Dam; Vasilis Ntziachristos; Sanjiv S Gambhir; Sophie Hernot; Stephan Rogalla Journal: Mol Imaging Biol Date: 2018-10 Impact factor: 3.488
Authors: Thinzar M Lwin; Sophie Hernot; Hannah Hollandsworth; Siamak Amirfakhri; Filemoni Filemoni; Pieterjan Debie; Robert M Hoffman; Michael Bouvet Journal: Surgery Date: 2020-05-04 Impact factor: 3.982
Authors: Nairo Brilhante-da-Silva; Rosa Maria de Oliveira Sousa; Andrelisse Arruda; Eliza Lima Dos Santos; Anna Carolina Machado Marinho; Rodrigo Guerino Stabeli; Carla Freire Celedonio Fernandes; Soraya Dos Santos Pereira Journal: Mol Diagn Ther Date: 2021-06-19 Impact factor: 4.074